X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
aged (10) 10
female (10) 10
middle aged (10) 10
chemotherapy (9) 9
male (9) 9
oncology (9) 9
index medicus (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
carcinoma, non-small-cell lung - drug therapy (7) 7
lung neoplasms - drug therapy (7) 7
adult (6) 6
treatment outcome (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carboplatin - administration & dosage (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease progression (4) 4
disease-free survival (4) 4
lung cancer (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - mortality (4) 4
lung neoplasms - pathology (4) 4
taxoids - administration & dosage (4) 4
cancer (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
care and treatment (3) 3
cisplatin (3) 3
cisplatin - administration & dosage (3) 3
gefitinib (3) 3
hematology, oncology and palliative medicine (3) 3
lung cancer, non-small cell (3) 3
pulmonary/respiratory (3) 3
radiation-therapy (3) 3
respiratory system (3) 3
survival (3) 3
adenocarcinoma (2) 2
aged, 80 and over (2) 2
anemia (2) 2
apoptosis (2) 2
article (2) 2
cancer patients (2) 2
carboplatin (2) 2
carboplatin - adverse effects (2) 2
clinical trials (2) 2
concurrent chemoradiotherapy (2) 2
deoxycytidine - adverse effects (2) 2
epidermal growth factor receptors (2) 2
erlotinib (2) 2
gemcitabine (2) 2
hemoglobin (2) 2
immunotherapy (2) 2
kaplan-meier estimate (2) 2
la-nsclc (2) 2
long-term survival (2) 2
lung neoplasms - therapy (2) 2
medicine & public health (2) 2
messenger-rna expression (2) 2
mutation (2) 2
non-small cell lung carcinoma (2) 2
open-label (2) 2
prognosis (2) 2
prognostic-factors (2) 2
quinazolines - therapeutic use (2) 2
receptor, epidermal growth factor - genetics (2) 2
taxoids - adverse effects (2) 2
therapy (2) 2
trial (2) 2
tumors (2) 2
1st-line therapy (1) 1
1st-line treatment (1) 1
7th edition (1) 1
adjuvants (1) 1
administration, oral (1) 1
advanced nsclc (1) 1
advanced pancreatic ductal adenocarcinoma (1) 1
adverse events (1) 1
agriculture (1) 1
amifostine (1) 1
anemia - complications (1) 1
anemia - drug therapy (1) 1
anthracyclines (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antimetabolites, antineoplastic - adverse effects (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, phytogenic - administration & dosage (1) 1
antineoplastic agents, phytogenic - adverse effects (1) 1
antineoplastic agents, phytogenic - therapeutic use (1) 1
apoptosis - drug effects (1) 1
apoptosis - genetics (1) 1
apoptosis regulatory proteins - genetics (1) 1
apoptosis regulatory proteins - metabolism (1) 1
b7-h1 antigen - analysis (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
bcl-2-like protein 11 (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 5, pp. 435 - 444
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2016, Volume 115, Issue 7, pp. 789 - 796
Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored... 
IMM-101 | phase II | immunomodulator | pancreatic cancer | advanced pancreatic ductal adenocarcinoma | Mycobacterium obuense | immunotherapy | gemcitabine | SURVIVAL | FOLFIRINOX | SAFETY | ADENOCARCINOMA | TRIAL | ONCOLOGY
Journal Article
Lung Cancer, ISSN 0169-5002, 2013, Volume 81, Issue 1, pp. 84 - 90
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 17499
BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may... 
APOPTOSIS | THERAPY | MESSENGER-RNA EXPRESSION | EURTAC | MULTIDISCIPLINARY SCIENCES | KINASE | MUTATIONS | BRCA1 | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Middle Aged | Apoptosis - genetics | Lung Neoplasms - pathology | Male | RNA, Messenger - metabolism | TOR Serine-Threonine Kinases - genetics | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Inhibitory Concentration 50 | Female | Membrane Proteins - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Membrane Proteins - genetics | RNA, Messenger - genetics | Proto-Oncogene Proteins - genetics | Treatment Outcome | Signal Transduction - genetics | Mutation - genetics | Apoptosis Regulatory Proteins - metabolism | Disease-Free Survival | Signal Transduction - drug effects | Quinazolines - therapeutic use | Erlotinib Hydrochloride - pharmacology | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Cohort Studies | Tyrosine | TOR protein | Cell proliferation | Adenocarcinoma | Epidermal growth factor receptors | Lung cancer | Non-small cell lung carcinoma | Tumor cell lines | Gene expression | Kinases | Cell activation | Gefitinib | Protein-tyrosine kinase | BIM protein | Apoptosis | Phosphodiesterase
Journal Article
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 08/2002, Volume 94, Issue 16, p. 1211
  Patients receiving chemotherapy often develop anemia. Darbopoetin alfa is an erythropoiesis-stimulating glycoprotein that has been shown to be safe and... 
Chemotherapy | Anemia | Lung cancer | Clinical trials | Pharmaceuticals
Journal Article
Clinical and Translational Oncology, ISSN 1699-048X, 11/2009, Volume 11, Issue 11, pp. 727 - 736
Journal Article